Study of Tecovirimat for Human Monkeypox Virus (STOMP)

Tecovirimat 针对人猴痘病毒 (STOMP) 的研究

• 批准号: 10689623
• 负责人: Grace M Aldrovandi
• 金额: $ 588.21万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-13 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10689623
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Affect; Area; Biological Assay; Biological Markers; Clinical; Clinical Research; Clinical Trials; Collaborations; DNA Repository; Diagnosis; Genomics; HIV; HIV Infections; HIV-1; HIV/TB; Health; Human; Immunology; Infection; International; Intervention; Knowledge; Laboratories; Laboratory Research; Laboratory Study; Malignant Neoplasms; Measures; Mediating; Molecular; Monkeypox virus; Morbidity - disease rate; Oral Manifestations; Patients; Pharmacology; Population; Prevention; Procedures; Protocols documentation; Research; Research Personnel; Safety; Scientific Advances and Accomplishments; Site; Specimen; Standardization; Testing; Therapeutic; Therapeutic Studies; Training Support; Tuberculosis; United States National Institutes of Health; Viral; Viral hepatitis; assay development; comorbidity; data management; human DNA; improved; innovation; laboratory experience; mortality; novel; oral pathogen; programs; treatment guidelines; tuberculosis treatment; virology

PROJECT SUMMARY The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV therapeutics and improve the health of patients living with HIV/AIDS for 25 years. Rigorous scientific research conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for the competitive renewal of the ACTG Network Laboratory Center, we propose a transformative laboratory research agenda that draws on an international consortium of prominent clinical and laboratory investigators in collaboration with a world-class Statistical and Data Management Center to conduct leading edge laboratory research, testing, assay development and laboratory training for the support of innovative interventional clinical trials. The component ACTG Network Laboratory Center will improve scientific knowledge and technical capability by providing state-of-the-art laboratory support in the four NIH/DAIDS priority areas of strategies to cure HIV; improve the diagnosis and treatment of tuberculosis; identify strategies to cure infectious viral hepatitis; improve the treatment and prevention of non-infectious co-morbidities associated with HIV infection and evaluate novel interventions targeting HIV infection. In addition, the Laboratory Center will provide laboratory support for therapeutic studies of oral manifestations of HIV/AIDS and virally mediated cancers. The continued expansion of an effective, quality-assured laboratory program at domestic and international sites for protocol safety measures, state-of-the-art molecular assays for virology and mycobacteriology; immunology and biomarkers; pharmacology; genomics; and oral pathogens associated with HIV-1 infection, will provide the essential framework for advancing the scientific agenda of the ACTG Network. The Laboratory Center will continue to provide oversight of established specimen and human DNA repositories for the ACTG Network, harmonize specific laboratory testing and standardized operating procedures with other Networks where feasible and continue to support the laboratory training of technologists and investigators domestically and internationally.

项目总结